Ingredients by Nature receives patent approval for use of eriocitrin to support blood glucose

February 12, 2020

The U.S. Patent and Trademark Office has approved a patent for the use of eriocitrin in Ingredient By Nature’s ingredient formulations, such as Eriomin, a citrus flavonoid designed for blood glucose support.

The U.S. Patent and Trademark Office has approved a patent for the use of eriocitrin in Ingredient By Nature’s (IBN; Montclair, CA) ingredient formulations, such as Eriomin, a citrus flavonoid designed for blood glucose support. The specific patent claim states that eriocitrin can be used as, “A method of reducing blood glucose levels in a human subject in need thereof, comprising administering to the subject a composition comprising 100-200 mg eriocitrin once per day.”

“We couldn’t be happier with the progress we have made to recognize eriocitrin as a viable option for better health,” said Rob Brewster, president of IBN, in a press release. “Supported by a successful first clinical trial and now this patent, our line of Eriomin lemon flavonoid blends, which are primarily comprised of eriocitrin, provide powerful support to managing healthy blood glucose levels. We look forward to revealing additional significant results from ongoing research into the effect that eriocitrin can have on blood glucose levels later this year.”